MMP-8, His, Human

MMP-8, His, Human

Alteration of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) expression has been studied for various cardiac diseases, including dilated cardiomyopathy (DCM), with the significance of surrogate markers of extracellular matrix (ECM) remodeling. MMP-8 was identified only in myocardiocytes, while MMP-9 and TIMP-2 were present in both myocardiocytes and stroma, but with different intensity. The increasing intensity of MMP-8 and TIMP-2 immunoreactions was significantly associated with low HCS.
Z05655
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
MMP-8 (Phe21-Gly467)_x000D_
Accession # P22894		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized MMP-8, His, Human at 5μg/ml (100μl/well) on the plate can bind Anti­MMP­8 Antibody, hFc Tag. Test result was comparable to standard batch. Measured by its ability to cleave the fluorogenic peptide substrate, Mca­PLGL­Dpa­AR­NH2. The specific activity is > 300 pmoles/min/μg. Test result meets the standard
Expression System HEK293
Theoretical Molecular Weight 52.2 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 50mM Tris, 10mM CaCl2, 150mM NaCl (pH 7.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Background
Target Background Alteration of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) expression has been studied for various cardiac diseases, including dilated cardiomyopathy (DCM), with the significance of surrogate markers of extracellular matrix (ECM) remodeling. MMP-8 was identified only in myocardiocytes, while MMP-9 and TIMP-2 were present in both myocardiocytes and stroma, but with different intensity. The increasing intensity of MMP-8 and TIMP-2 immunoreactions was significantly associated with low HCS.
Synonyms MMP-8; PMNL-CL; CLG1; MMP8; Collagenase 2; PMNL-CL; HNC

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.